Low-Dose IL-2 and Alpha-Interferon for Metastatic Kidney Cancer
Author Information
Author(s): A. Ravaud, S. Negrier, L. Cany, Y. Merrouche, M. Le Guillou, J.Y. Blay, M. Clavel, R. Gaston, R. Oskam, T. Philip
Primary Institution: Fondation Bergonie, Comprehensive Cancer Centre, Bordeaux, France
Hypothesis
Can low-dose recombinant interleukin 2 and alpha-interferon effectively treat patients with metastatic renal cell carcinoma?
Conclusion
The study found that low-dose IL-2 and alpha-interferon can be safely administered with a modest objective response rate in patients with metastatic renal cell carcinoma.
Supporting Evidence
- An objective response was seen in seven patients, with one complete response and six partial responses.
- The median duration of response was 6.7 months.
- Toxicity was limited, with mild to moderate side effects including fever and fatigue.
- Patients with stable disease had a median survival of 14.2 months.
Takeaway
Doctors gave a special medicine to 38 people with kidney cancer to see if it would help them feel better, and some did get better for a little while.
Methodology
Patients received subcutaneous IL-2 and alpha-interferon over a 7-week period, with evaluations for response and toxicity.
Potential Biases
Potential selection bias due to exclusion criteria and the nature of the outpatient treatment.
Limitations
The study had a small sample size and the treatment was associated with significant toxicity.
Participant Demographics
The study included 38 patients, 28 males and 10 females, with a median age of 58 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
6.1-30.7%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website